Unmet medical needs in systemic lupus erythematosus

Arthritis Research and Therapy

Volumn 14, Issue SUPPL. 4, 2012, Pages

  Lateef, Aisha ^a   Petri, Michelle ^b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAPSONE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID; PLACEBO; RETINOID; RITUXIMAB; THALIDOMIDE;

ATHEROSCLEROSIS; CLINICAL RESEARCH; CORTICOSTEROID THERAPY; EARLY DIAGNOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS; QUALITY OF LIFE; REVIEW; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84871505213     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3919     Document Type: Review

References (94)

1. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277. 10.1002/art.1780251101, 7138600.
2. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerro J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khasmashta MA, Jacobsen S, Buyon JP, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012, 64:2677-2686. 10.1002/art.34473, 22553077.
3. Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001, 44:2342-2349. 10.1002/1529-0131(200110)44:10<2342::AID-ART397>3.0.CO;2-8, 11665975.
4. Liu CC, Ahearn JM. The search for lupus biomarkers. Best Pract Res Clin Rheumatol 2009, 23:507-523. 10.1016/j.berh.2009.01.008, 2727983, 19591781.
5. Niewold TB, Kelly JA, Kariuki SN, Franek BS, Kumar AA, Kaufman KM, Thomas K, Walker D, Kamp S, Frost JM, Wong AK, Merrill JT, Alarcon-Riquelme NE, Tikly M, Ramsey-Goldman R, Reveille JD, Petri MA, Edberg JC, Kimberly RP, Alarcon GS, Kamen DL, Gilkeson GS, Vyse TJ, James JA, Gaffney PM, Moser KL, Crow MK, Harley JB. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis 2012, 71:463-468. 10.1136/annrheumdis-2011-200463, 22088620.
6. Hughes T, Adler A, Kelly JA, Kaufman KM, Williams AH, Langefeld CD, Brown EE, Alarcon GS, Kimberly RP, Edberg JC, Ramsey-Goldman R, Petri M, Boackle SA, Stevens AM, Reveille JD, Sanchez E, Martin J, Niewold TB, Vila LM, Scofield RH, Gilkeson GS, Gaff ney PM, Criswell LA, Moser KL, Merrill JT, Jacob CO, Taso BP, James JA, Vyse TJ, Alarcon-Riquelme ME, , Harley JB, Richardson BC, Sawalha AH. BIOLUPUS Network Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupus erythematosus. Arthritis Rheum 2012, 64:485-492. 10.1002/art.33354, 21952918, BIOLUPUS Network.
7. Seyhan A, Toole MA, Zhang Y, Immermann FW, Hill A, Reddy P, Masferrer J, Zhou T, Mounts W, Whitley M. Impact of baseline Interferon pathway activation on widespread gene expression changes with disease flare in lupus patients: interim report from the BOLD (Biomarkers of lupus disease) study. Ann Rheum Dis 2012, 71(Suppl 3):74.
8. Fernando MM, Freudenberg J, Lee A, Morris DL, Boteva L, Rhodes B, Gonzalez-Escribano MF, Lopez-Nevot MA, Navarra SV, Gregersen PK, Martin J, Vyse TJ. Transancestral mapping of the MHC region in systemic lupus erythematosus identifies new independent and interacting loci at MSH5, HLA-DPB1 and HLA-G. Ann Rheum Dis 2012, 71:777-784. 10.1136/annrheumdis-2011-200808, 3329227, 22233601.
9. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005, 52:1491-1503. 10.1002/art.21031, 15880830.
10. Petri M, Singh S, Tesfasyone H, Dedrick R, Fry K, Lal P, Williams G, Bauer J, Gregersen P, Behrens T, Baechler E. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009, 18:980-989. 10.1177/0961203309105529, 19762399.
11. Landolt-Marticorena C, Bonventi G, Lubovich A, Ferguson C, Unnithan T, Su J, Gladman DD, Urowitz M, Fortin PR, Wither J. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2009, 68:1440-1446. 10.1136/ard.2008.093146, 18772188.
12. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008, 58:2453-2459. 10.1002/art.23678, 18668552.
13. Akhter E, Burlingame RW, Seaman AL, Magder L, Petri M. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus 2011, 20:1267-1274. 10.1177/0961203311411597, 21813587.
14. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sanchez-Guerrero J, Solomons N, Wofsy D, . Aspreva Lupus Management Study Group Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009, 20:1103-1112. 10.1681/ASN.2008101028, 2678035, 19369404, Aspreva Lupus Management Study Group.
15. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli HGaleazzi M, Gül A, Levy Y, Petera P, Popovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Carvera R. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010, 69:61-64. 10.1136/ard.2008.102533, 19155235.
16. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sanchez-Guerrero J, Wofsy D, Yu X, Solomons N. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010, 49:128-140. 10.1093/rheumatology/kep346, 2789586, 19933596.
17. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N, ALMS G. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011, 365:1886-1895. 10.1056/NEJMoa1014460, 22087680.
18. Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, Fiehn C, de Ramon Garrido E, Gilboe IM, Tektonidou M, Blockmans D, Ravelinigien I, le Guern V, Depresseux G, Guillevin L, Cervera R, . MAINTAIN Nephritis Trial Group Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010, 69:2083-2089. 10.1136/ard.2010.131995, 3002764, 20833738, MAINTAIN Nephritis Trial Group.
19. Chen W, Liu Q, Tang X, Fu P, Liu F, Liao Y, Yang Z, Zhang J, Chen J, Lou T, Fu J, Kong Y, Liu Z, Li Z, Yu X. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 2012, 21:944-952. 10.1177/0961203312442259, 22438027.
20. Wang S, Li X, Qu L, Wang R, Chen Y, Li Q, He X, Zhang X, Wang H, Wu J, Xu Y, Chen J. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study. Lupus 2012, 21:1025-1035. 10.1177/0961203312448105, 22570338.
21. Zavada J, Pesickova S, Rysava R, Olejarova M, Horak P, Hrncir Z, Rychlik I, Havrda M, Vitova J, Lukac J, Rovensky J, Tegzova D, Böhmova J, Zadrazil J, Hána J, Dostál C, Tesar V. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus 2010, 19:1281-1289. 10.1177/0961203310371155, 20605876.
22. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off -label use in 188 cases. Lupus 2009, 18:767-776. 10.1177/0961203309106174, 19578100.
23. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G, . LUNAE Investigator Group Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012, 64:1215-1226. 10.1002/art.34359, 22231479, LUNAE Investigator Group.
24. Lateef A, Petri M. Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol 2010, 22:504-509. 10.1097/BOR.0b013e32833b475e, 20502332.
25. Weidenbusch M, Rommele C, Schrottle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 2012,
26. Diaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martinez-Berriotxoa A, Garcia-Hernandez F, Callejas-Rubio JL, Rascon J, D'Cruz D, Jayne D, Ruiz-Irastorza G, Emery P, Isenberg D, Ramos-Casals M, Khamashta MA, . UK-BIOGEAS Registry Efficacy of rituximab in 164 patients with biopsyproven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012, 11:357-364. 10.1016/j.autrev.2011.10.009, 22032879, UK-BIOGEAS Registry.
27. Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006, 15:366-370. 10.1191/0961203306lu2313oa, 16830883.
28. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010, 69:20-28. 10.1136/ard.2008.101766, 19103632.
29. Kitamura N, Matsukawa Y, Takei M, Sawada S. Antiproteinuric effect of angiotensin-converting enzyme inhibitors and an angiotensin II receptor blocker in patients with lupus nephritis. J Int Med Res 2009, 37:892-898.
30. Duran-Barragan S, McGwin G, Vila LM, Reveille JD, Alarcon GS. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): amultiethnic US cohort. Rheumatology (Oxford) 2008, 47:1093-1096. 10.1093/rheumatology/ken208, 2916239, 18511474.
31. Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford) 2011, 50:1424-1430. 10.1093/rheumatology/ker101, 21415024.
32. Ward MM. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004. J Rheumatol 2009, 36:63-67. 2679678, 19004042.
33. Barr RG, Seliger S, Appel GB, Zuniga R, D'Agati V, Salmon J, Radhakrishnan J. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant 2003, 18:2039-2046. 10.1093/ndt/gfg345, 13679478.
34. Costenbader KH, Desai A, Alarcon GS, Hiraki LT, Shaykevich T, Brookhart MA, Massarotti E, Lu B, Solomon DH, Winkelmayer WC. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum 2011, 63:1681-1688. 10.1002/art.30293, 3106117, 21445962.
35. Santiago-Casas Y, Vila LM, McGwin G, Cantor RS, Petri M, Ramsey-Goldman R, Reveille JD, Kimberly RP, Alarcon GS, Brown EE. Association of discoid lupus erythematosus with clinical manifestations and damage accrual in a multiethnic lupus cohort. Arthritis Care Res (Hoboken) 2012, 64:704-712. 10.1002/acr.21581, 22190480.
36. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part I. J Am Acad Dermatol 2011, 65:e179-e193. 10.1016/j.jaad.2010.06.018, 20739095.
37. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol 2011, 65:e195-e213. 10.1016/j.jaad.2010.06.017, 20800319.
38. Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2009, 4:CD002954.
39. ACR adhoc Committee on Neuropsychiatric Lupus Nomenclature The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999, 42:599-608. ACR adhoc Committee on Neuropsychiatric Lupus Nomenclature.
40. Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsanoja R, Auvinen A. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum 2001, 45:419-423. 10.1002/1529-0131(200110)45:5<419::AID-ART360>3.0.CO;2-X, 11642640.
41. Karassa FB, Afeltra A, Ambrozic A, Chang DM, De Keyser F, Doria A, Galeazzi M, Hirohata S, Hoffman IE, Inanc M, Massardo L, Mathieu A, Mok CC, Morozzi G, Sanna G, Spindler AJ, Tzioufas AG, Yoshio T, Ioannidis JP. Accuracy of antiribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006, 54:312-324. 10.1002/art.21539, 16385548.
42. Okamoto H, Kobayashi A, Yamanaka H. Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus. J Biomed Biotechnol 2010, 2010:268436. 2896663, 20617145.
43. Luyendijk J, Steens SC, Ouwendijk WJ, Steup-Beekman GM, Bollen EL, van der Grond J, Huizinga TW, Emmer BJ, van Buchem MA. Neuropsychiatric systemic lupus erythematosus: lessons learned from magnetic resonance imaging. Arthritis Rheum 2011, 63:722-732. 10.1002/art.30157, 21360502.
44. Petri M, Naqibuddin M, Carson KA, Sampedro M, Wallace DJ, Weisman MH, Holliday SL, Padilla PA, Brey RL. Cognitive function in a systemic lupus erythematosus inception cohort. J Rheumatol 2008, 35:1776-1781.
45. Petri M, Naqibuddin M, Carson KA, Wallace DJ, Weisman MH, Holliday SL, Sampedro M, Padilla PA, Brey RL. Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus. J Rheumatol 2010, 37:2032-2038. 10.3899/jrheum.091366, 20634244.
46. Kozora E, Ellison MC, West S. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Rheum 2006, 55:628-635. 10.1002/art.22101, 16874786.
47. Petri M, Naqibuddin M, Sampedro M, Omd al R, Carson KA. Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial. Semin Arthritis Rheum 2011, 41:194-202. 10.1016/j.semarthrit.2011.02.005, 3153605, 21458845.
48. Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, Cervera R, Dalakas M, Doria A, Hanly JG, Huizinga TW, Isenberg D, Kallenberg C, Piette JC, Schneider M, Scolding N, Smolen J, Stara A, Tassiulas I, Tektonidou M, Tincani A, van Buchem MA, van Vollenhoven R, Ward M, Gordon C, Boumpas DT. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010, 69:2074-2082. 10.1136/ard.2010.130476, 20724309.
49. Nossent J, Cikes N, Kiss E, Marchesoni A, Nassonova V, Mosca M, Olesinska M, Pokorny G, Rozman B, Schneider M, Vlachioyiannopoulos PG, Swaak A. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual. Lupus 2007, 16:309-317. 10.1177/0961203307077987, 17576731.
50. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Cote R, Grover SA, Fortin PR, Clarke AE, Senécal JL. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44:2331-2337. 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I, 11665973.
51. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399-2406. 10.1056/NEJMoa035471, 14681505.
52. McMahon M, Grossman J, Skaggs B, Fitzgerald J, Sahakian L, Ragavendra N, Charles-Schoeman C, Watson K, Wong WK, Volkmann E, Chen W, Gorn A, Karpouzas G, Weisman M, Wallace DJ, Hahn BH. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009, 60:2428-2437. 10.1002/art.24677, 2753974, 19644959.
53. Wright SA, O'Prey FM, Rea DJ, Plumb RD, Gamble AJ, Leahey WJ, Devine AB, McGivern RC, Johnston DG, Finch MB, Bell AL, McVeigh GE. Microcirculatory hemodynamics and endothelial dysfunction in systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2006, 26:2281-2287. 10.1161/01.ATV.0000238351.82900.7f, 16873725.
54. Somers EC, Zhao W, Lewis EE, Wang L, Wing JJ, Sundaram B, Kazerooni EA, McCune WJ, Kaplan MJ. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One 2012, 7:e37000. 10.1371/journal.pone.0037000, 3351452, 22606325.
55. Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, Sandy AR, McCune WJ, Kaplan MJ. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol 2010, 184:3284-3297. 10.4049/jimmunol.0902199, 2929645, 20164424.
56. Huang Q, Pope RM. Toll-like receptor signaling: a potential link among rheumatoid arthritis, systemic lupus, and atherosclerosis. J Leukoc Biol 2010, 88:253-262. 10.1189/jlb.0310126, 2908942, 20484668.
57. Matsuura E, Lopez LR, Shoenfeld Y, Ames PR. β2-glycoprotein I and oxidative inflammation in early atherogenesis: a progression from innate to adaptive immunity?. Autoimmun Rev 2012, 12:241-249. 10.1016/j.autrev.2012.04.003, 22569463.
58. Kiani AN, Magder L, Petri M. Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. J Rheumatol 2008, 35:1300-1306.
59. Maksimowicz-McKinnon K, Magder LS, Petr i M. Predictors of carotid atherosclerosis in systemic lupus erythematosus. J Rheumatol 2006, 33:2458-2463.
60. Kiani AN, Vogel-Claussen J, Magder LS, Petri M. Noncalcified coronary plaque in systemic lupus erythematosus. J Rheumatol 2010, 37:579-584. 10.3899/jrheum.090824, 20110529.
61. Kiani AN, Mahoney JA, Petri M. Asymmetric dimethylarginine is a marker of poor prognosis and coronary calcium in systemic lupus erythematosus. J Rheumatol 2007, 34:1502-1505.
62. McMahon M, Skaggs BJ, Sahakian L, Grossman J, FitzGerald J, Ragavendra N, Charles-Schoeman C, Chernishof M, Gorn A, Witztum JL, Wong WK, Weisman M, Wallace DJ, La Cava A, Hahn BH. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann Rheum Dis 2011, 70:1619-1624. 10.1136/ard.2010.142737, 3147230, 21670088.
63. Roman MJ, Crow MK, Lockshin MD, Devereux RB, Paget SA, Sammaritano L, Levine DM, Davis A, Salmon JE. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007, 56:3412-3419. 10.1002/art.22924, 17907140.
64. Gustafsson J, Simard JF, Gunnarsson I, Elvin K, Lundberg IE, Hansson LO, Larsson A, Svenungsson E. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther 2012, 14:R46. 10.1186/ar3759, 22390680.
65. Petri MA, Kiani AN, Post W, Christopher-Stine L, Magder LS. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011, 70:760-765. 10.1136/ard.2010.136762, 21177297.
66. Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, Mieszkalski KL, Ilowite NT, Eberhard A, Imundo LF, Kirmua Y, von Scheven E, Silverman E, Bowyer SL, Punaro M, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunnger HI, Jung L, Soep JB, Reed AM, Provenzale J, Thompson SD, . Athesrosclerosis Prevention in Pediatric Lupus Erythematosus Investigators Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum 2012, 64:285-296. 10.1002/art.30645, 22031171, Athesrosclerosis Prevention in Pediatric Lupus Erythematosus Investigators.
67. Kiani AN, Magder LS, Petri M. Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years. Rheumatol Int 2012, 32:2701-2705. 10.1007/s00296-011-2048-y, 21792642.
68. van Leuven SI, Mendez-Fernandez YV, Wilhelm AJ, Wade NS, Gabriel CL, Kastelein JJ, Stroes ES, Tak PP, Major AS. Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice. Ann Rheum Dis 2012, 71:408-414. 10.1136/annrheumdis-2011-200071, 21953346.
69. Thamer M, Hernan MA, Zhang Y, Cotter D, Petri M. Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009, 36:560-564. 10.3899/jrheum.080828, 19208608.
70. Magder L, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythamatosus. Am J Epidemiol 2012, 176:708-719. 10.1093/aje/kws130, 23024137.
71. Choi ST, Kang JI, Park IH, Lee YW, Song JS, Park YB, Lee SK. Subscale analysis of quality of life in patients with systemic lupus erythematosus: association with depression, fatigue, disease activity and damage. Clin Exp Rheumatol 2012, 30:664-672.
72. Pettersson S, Lovgren M, Eriksson L, Moberg C, Svenungsson E, Gunnarsson I, Welin Henriksson E. An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life. Scand J Rheumatol 2012, 41:383-390. 10.3109/03009742.2012.677857, 22646821.
73. Zonana-Nacach A, Roseman JM, McGwin G, Friedman AW, Baethge BA, Reveille JD, Alarcon GS. Systemic lupus erythematosus in three ethnic groups. VI: factors associated with fatigue within 5 years of criteria diagnosis. LUMINA Study Group. LUpus in MInority populations: NAture vs Nurture. Lupus 2000, 9:101-109. 10.1191/096120300678828046, 10787006.
74. Burgos PI, Alarcon GS, McGwin G, Crews KQ, Reveille JD, Vila LM. Disease activity and damage are not associated with increased levels of fatigue in systemic lupus erythematosus patients from a multiethnic cohort: LXVII. Arthritis Rheum 2009, 61:1179-1186. 10.1002/art.24649, 2748186, 19714612.
75. Jump RL, Robinson ME, Armstrong AE, Barnes EV, Kilbourn KM, Richards HB. Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. J Rheumatol 2005, 32:1699-1705.
76. Tench CM, McCarthy J, McCurdie I, White PD, D'Cruz DP. Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise. Rheumatology (Oxford) 2003, 42:1050-1054. 10.1093/rheumatology/keg289, 12730519.
77. Moses N, Wiggers J, Nicholas C, Cockburn J. Prevalence and correlates of perceived unmet needs of people with systemic lupus erythematosus. Patient Educ Couns 2005, 57:30-38. 10.1016/j.pec.2004.03.015, 15797150.
78. Buskila D, Press J, Abu-Shakra M. Fibromyalgia in systemic lupus erythematosus: prevalence and clinical implications. Clin Rev Allergy Immunol 2003, 25:25-28. 10.1385/CRIAI:25:1:25, 12794258.
79. Torrente-Segarra V, Carbonell-Abello J, Castro-Oreiro S, Manresa Dominguez JM. Association between fibromyalgia and psychiatric disorders in systemic lupus erythematosus. Clin Exp Rheumatol 2010, 28(6 Suppl 63):S22-S26.
80. Friedman AW, Tewi MB, Ahn C, McGwin G, Fessler BJ, Bastian HM, Baethge BA, Reveille JD, Alarcon GS. Systemic lupus erythematosus in three ethnic groups: XV. Prevalence and correlates of fibromyalgia. Lupus 2003, 12:274-279. 10.1191/0961203303lu330oa, 12729050.
81. Bachen EA, Chesney MA, Criswell LA. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum 2009, 61:822-829. 10.1002/art.24519, 2763591, 19479699.
82. Meszaros ZS, Perl A, Faraone SV. Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J Clin Psychiatry 2012, 73:993-1001. 10.4088/JCP.11r07425, 22687742.
83. Moldovan I, Katsaros E, Carr FN, Cooray D, Torralba K, Shinada S, Ishimori ML, Jolly M, Wallace DJ, Weisman MH, Nicassio PM. The Patient Reported Outcomes in Lupus (PATROL) study: role of depression in health-related quality of life in a Southern California lupus cohort. Lupus 2011, 20:1285-1292. 10.1177/0961203311412097, 21813589.
84. Giovacchini G, Mosca M, Manca G, Della Porta M, Neri C, Bombardieri S, Ciarmiello A, Strauss HW, Mariani G, Volterrani D. Cerebral blood flow in depressed patients with systemic lupus erythematosus. J Rheumatol 2010, 37:1844-1851. 10.3899/jrheum.100121, 20595265.
85. Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck-Spencer T, Weickert T, Bleiberg J, Rosenstein D, Pao M, Patronas N, Steele S, Manzano M, van der Veen JW, Lipsky PE, Marneco S, Wesley R, Volpe B, Diamond B, Illei GG. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006, 54:2505-2514. 10.1002/art.22031, 16868971.
86. Nikpour M, Urowitz MB, Ibanez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009, 61:1152-1158. 10.1002/art.24741, 19714602.
87. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233. 10.1002/art.27233, 20039413.
88. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, . BLISS-76 Study Group A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011, 63:3918-3930. 10.1002/art.30613, 22127708, BLISS-76 Study Group.
89. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, Leon MG, Tanasescu C, Nasanov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, . BLISS-52 Study Group Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731. 10.1016/S0140-6736(10)61354-2, 21296403, BLISS-52 Study Group.
90. Guidance for Industry, Systemic Lupus Erythematosus - Developing Medical Products for Treatment. , http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072063.pdf
91. Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999, 8:685-691. 10.1191/096120399680411281, 10568907.
92. Wollaston SJ, Farewell VT, Isenberg DA, Gordon C, Merrill JT, Petri MA, Kalunian KC. Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. J Rheumatol 2004, 31:2390-2394.
93. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009, 61:1143-1151. 10.1002/art.24698, 2748175, 19714615.
94. Hahn BH. Targeted therapies in systemic lupus erythematosus: successes, failures and future. Ann Rheum Dis 2011, 70(Suppl 1):i64-i66. 10.1136/ard.2010.142208, 21339222.